Swiss National Bank Boosts Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Swiss National Bank lifted its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 2.2% in the fourth quarter, Holdings Channel reports. The firm owned 65,600 shares of the company’s stock after acquiring an additional 1,400 shares during the period. Swiss National Bank’s holdings in TransMedics Group were worth $4,090,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its holdings in shares of TransMedics Group by 11.3% in the third quarter. Victory Capital Management Inc. now owns 4,569 shares of the company’s stock valued at $717,000 after acquiring an additional 464 shares during the period. Mutual of America Capital Management LLC acquired a new stake in TransMedics Group during the 3rd quarter worth $784,000. Charles Schwab Investment Management Inc. grew its position in TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the last quarter. Bank of Montreal Can increased its stake in TransMedics Group by 1.2% in the third quarter. Bank of Montreal Can now owns 69,973 shares of the company’s stock valued at $11,136,000 after purchasing an additional 809 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of TransMedics Group by 3.7% in the third quarter. The Manufacturers Life Insurance Company now owns 18,473 shares of the company’s stock valued at $2,900,000 after buying an additional 657 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Robert W. Baird cut their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $70.79 on Wednesday. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The business’s 50-day simple moving average is $68.43 and its 200-day simple moving average is $89.16. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market capitalization of $2.38 billion, a P/E ratio of 75.31 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.